Next Article in Journal
Personalised Medicine: The Odyssey from Hope to Practice
Previous Article in Journal
Individualized Transcriptional Resolution of Complicated Malaria in a Colombian Study
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
J. Pers. Med. 2018, 8(3), 30; https://doi.org/10.3390/jpm8030030

The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology

1
Division of Health Informatics, Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY 10065, USA
2
Division of Medical Oncology, Weill Cornell Medicine and New York-Presbyterian Hospital, New York, NY 10065, USA
3
Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA
4
Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY 10065, USA
5
Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10065, USA
*
Author to whom correspondence should be addressed.
Received: 3 July 2018 / Revised: 7 September 2018 / Accepted: 10 September 2018 / Published: 17 September 2018
Full-Text   |   PDF [822 KB, uploaded 17 September 2018]   |  

Abstract

Precision medicine seeks to use genomic data to help provide the right treatment to the right patient at the right time. Next-generation sequencing technology allows for the rapid and accurate sequencing of many genes at once. This technology is becoming more common in oncology, though the clinical benefit of incorporating it into precision medicine strategies remains under significant debate. In this manuscript, we discuss the early findings of the impact of next-generation sequencing on cancer patient outcomes. We investigate why not all patients with genomic variants linked to a specific therapy receive that therapy and describe current barriers. Finally, we explore the current state of health insurance coverage for individual genome sequencing and targeted therapies for cancer. Based on our analysis, we recommend increased transparency around the determination of “actionable mutations” and a heightened focus on investigating the variations in health insurance coverage across patients receiving sequencing-matched therapies. View Full-Text
Keywords: precision medicine; next generation sequencing; oncology; patient outcomes; health insurance coverage precision medicine; next generation sequencing; oncology; patient outcomes; health insurance coverage
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Morash, M.; Mitchell, H.; Beltran, H.; Elemento, O.; Pathak, J. The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology. J. Pers. Med. 2018, 8, 30.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top